Rare pediatric PRV program not linked to uptick in new drugs starting trials, study finds

The rare pediatric priority review voucher (PRV) program was not found to be associated with an increase in the number or rate of new rare pediatric disease drugs that began clinical trials, a Health Affairs study found.